Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,079 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07354087 | Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry(IMPACTEndoAsia) | active not recruiting | — | 300 | Tata Memorial HospitalOTHER_GOV | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 |
| clinicaltrials |
| NCT07338526 | Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)(IMPORT) | recruiting | N/A | 94 | Tata Memorial CentreOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07367334 | Effects of MMV Exercise With and Without Verbal Guidance on Shoulder Movement, Fatigue, and Stress in Breast Cancer Survivors | completed | N/A | 34 | Saveetha UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT03853655 | Adjuvant Radiotherapy in Early Stage Oral Cancers(AREST) | completed | N/A | 392 | Tata Memorial HospitalOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT05512169 | Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia(MPGx-INDALL) | recruiting | — | 556 | University of Geneva, SwitzerlandOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07342231 | FAPi PET in Pancreatic Ductal Adenocarcinoma(FAP-1) | recruiting | — | 60 | Tata Memorial HospitalOTHER_GOV | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03056755 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments(BYLieve) | completed | Phase 2 | 383 | Novartis PharmaceuticalsINDUSTRY | 19 | Jan 13, 2026 | clinicaltrials |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)(STIMULUS-MDS2) | terminated | Phase 3 | 530 | Novartis PharmaceuticalsINDUSTRY | 36 | Jan 13, 2026 | clinicaltrials |
| NCT06755450 | Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma(ADITI-1) | recruiting | Phase 1 | 40 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337850 | Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers(FAPi-2) | recruiting | — | 60 | Tata Memorial CentreOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT01856478 | LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 340 | Boehringer IngelheimINDUSTRY | 8 | Jan 12, 2026 | clinicaltrials |
| NCT03974893 | Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children With Acute Lymphoblastic Leukemia(TATA) | active not recruiting | — | 115 | Columbia UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT06909188 | The Study of Association of Helicobacter Infections in Biliary Tract Cancers | recruiting | — | 250 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant(REACH 5) | completed | Phase 2 | 46 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 11, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT06189209 | Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 40 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07258797 | Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer(SHOOL) | not yet recruiting | N/A | 150 | Rajiv Gandhi Cancer Institute & Research Center, IndiaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT03052608 | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | active not recruiting | Phase 3 | 296 | PfizerINDUSTRY | 23 | Nov 25, 2025 | clinicaltrials |
| NCT07249021 | This is a Multicentre International Study Evaluating CT-based IGABT With / Without Either TRUS During BT/Pre BT MR as Per IBS-GECESTRO-ABS Recommendations for Target contouring-as an Alternative to MRIGABT for Cervical Cancer From Implementation Perspectives Under EMBRACE-III:TRIPLET IMPACT Study.(IMPACT) | not yet recruiting | — | 1,200 | Homi Bhabha Cancer Hospital & Research CentreOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03703297 | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy(ADRIATIC) | active not recruiting | Phase 3 | 730 | AstraZenecaINDUSTRY | 19 | Nov 21, 2025 | clinicaltrials |
| NCT03822468 | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer(AMALEE) | completed | Phase 2 | 376 | Novartis PharmaceuticalsINDUSTRY | 23 | Oct 16, 2025 | clinicaltrials |
| NCT02625389 | A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures | completed | Phase 4 | 132 | GuerbetINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04057209 | VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer(VoiceS) | recruiting | N/A | 34 | Olgun ElicinOTHER | 3 | Oct 7, 2025 | clinicaltrials |
| NCT05564052 | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma(VEGA) | completed | Phase 2 | 36 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 7, 2025 | clinicaltrials |
| NCT01496313 | To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | completed | Phase 4 | 81 | SanofiINDUSTRY | 9 | Oct 3, 2025 | clinicaltrials |
| NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2(REGAL) | active not recruiting | Phase 3 | 127 | Sellas Life Sciences GroupINDUSTRY | 10 | Oct 1, 2025 | clinicaltrials |
| NCT00410761 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | completed | Phase 3 | 331 | Genzyme, a Sanofi CompanyINDUSTRY | 24 | Sep 24, 2025 | clinicaltrials |
| NCT07185672 | PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)(PReCedeNT) | recruiting | Phase 3 | 162 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06927102 | From Exclusion to Inclusion: Analysing Follow-up Discontinuity in Breast Cancer(FOCUS-BC) | recruiting | — | 1,500 | Basavatarakam Indo American Cancer Hospital & Research InstituteOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06131424 | NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients(iRetroBC) | completed | — | 1,151 | AstraZenecaINDUSTRY | 13 | Sep 18, 2025 | clinicaltrials |
| NCT06831461 | Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors(PRIDE) | recruiting | N/A | 156 | Tata Memorial CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT00532155 | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer(VITAL) | completed | Phase 3 | 913 | SanofiINDUSTRY | 32 | Sep 10, 2025 | clinicaltrials |
| NCT03797482 | A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer(Hypoxia) | recruiting | — | 500 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04919226 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE(COMPOSE) | active not recruiting | Phase 3 | 259 | ITM Solucin GmbHINDUSTRY | 10 | Sep 10, 2025 | clinicaltrials |
| NCT05236946 | Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05277844 | Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC(TARGET-01) | recruiting | Phase 2 | 106 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05278052 | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC(TARGET-02) | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05742711 | Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients | completed | N/A | 48 | DyAnsys, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | completed | Phase 2 | 133 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 29, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04655469 | Personal Health Train for Radiation Oncology in India and The Netherlands(TRAIN) | active not recruiting | — | 2,000 | Maastricht Radiation OncologyOTHER | 2 | Aug 22, 2025 | clinicaltrials |
| NCT07138378 | A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.(XS003-11) | completed | Phase 1 | 128 | Xspray Pharma ABINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | completed | Phase 3 | 545 | Novartis PharmaceuticalsINDUSTRY | 23 | Aug 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials